Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A ~~process for identifying a compound which~~method for selectively binding adenine nucleotide translocator (ANT) and ~~induces~~ inducing the mitochondrial permeability transition (MPT) in a proliferating cell but not in a non-proliferating or growth quiescent cell in a mammal, the method comprising administering to the mammal an effective amount of a compound that selectively induces the MPT in a proliferating cell. ~~compared to a non-proliferating cell or growth quiescent cell, wherein said process comprises~~

~~(a) (i) contacting a proliferating cell or cell extract with a compound, and~~

~~(ii) contacting a non-proliferating or growth quiescent cell or cell extract with the compound,~~

~~(b) measuring binding of the compound to adenine nucleotide translocator (ANT) in the proliferating cell or cell extract,~~

~~wherein the compound binds to ANT in the proliferating cell or cell extract, and~~

~~(c) (i) measuring the induction of the MPT in the proliferating cell or cell extract, and~~

~~(ii) measuring the induction of the MPT in the non-proliferating or growth quiescent cell or cell extract,~~

~~wherein, the compound selectively induces the MPT in the proliferating cell or cell extract but not in the non-proliferating or growth quiescent cell or cell extract.~~

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (withdrawn) A process of inducing MPT in a vertebrate, wherein the method comprises administering to the vertebrate a therapeuctically effective amount of at least one compound identified in accordance with the process of claim 1, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said compounds together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

7. (withdrawn) A process of inducing apoptosis in proliferating mammalian cells, comprising administering to the mammal an apoptosis-inducing amount of a compound identified in accordance with the process of claim 1, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of the compounds together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

8. (withdrawn) A process of inhibiting angiogenesis in a mammal, comprising administering to the mammal an angiogenesis-inhibiting amount of a compound identified in accordance with the process of claim 1, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said compounds together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

9. (Currently amended) The ~~process~~ method of claim 1, wherein the compound is a dithiol reactive compound.

10. (Currently amended) The ~~process~~ method of claim 1, wherein the compound has an arsenoxide (or arsenoxide equivalent) moiety.

11. (Currently amended) The ~~process~~ method of claim 10, wherein the compound is of the formula (I):

$$A\text{-}[(XBX')_nB'\text{-}Y]_p \qquad (I)$$

wherein

A comprises at least one pendant group;

$(XBX')_nB'$ comprises a suitable linker group, wherein X is selected from the group consisting of -NR, -S(O)-, -S(O)O-, $-S(O)_2-$, $-S(O)_2O-$, -C(O)-, -C(S)-, -C(O)O-, C(S)O-, -C(S)S-, -P(O)(R_1)-, and -P(O)(R_1)O-, or is absent;

B is selected from the group consisting of C_1-C_{10} alkylene, C_2-C_{10} alkenylene, C_2-C_{10} alkynylene, C_3-C_{10} cycloalkylene, C_5-C_{10} cycloalkenylene, C_3-C_{10} heterocycloalkylene, C_5-C_{10} heterocycloalkenylene, C_6-C_{12} arylene, heteroarylene and C_2-C_{10} acyl;

X' is selected from the group consisting of -NR-, -O-, -S-, -Se-, -S-S-, S(O)-, -OS(O)-, OS(O)O-, $-OS(O)_2$, $-OS(O)_2O-$, $-S(O)O-$, $-S(O)_2-$, $-S(O)_2O-$, -OP(O)(R_1)-, -OP(O)(R_1)O-, -OP(O)(R_1)OP(O)(R_1)O-, -C(O)-, -C(S)-, -C(O)O-, C(S)O-, -C(S)S-, -P(O)(R_1)-, -P(O)(R_1)O-, and



or is absent; wherein E is O, S, Se, NR or $N(R)_2^+$;

B' is selected from the group consisting of C_1-C_{10} alkylene, C_2-C_{10} alkenylene, C_2-C_{10} alkynylene, C_3-C_{10} cycloalkylene, C_5-C_{10} cycloalkenylene, C_3-C_{10} heterocycloalkylene, C_5-C_{10} heterocycloalkenylene, C_6-C_{12} arylene, and heteroarylene or is absent; and wherein

each R is independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_3-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, C_6-C_{12} aryl, heteroaryl, OR_2 and C_2-C_{10} acyl;

R' is the same as R or two R' may be taken together with the nitrogen atoms to which they are attached to form a 5 or 6-membered saturated or unsaturated heterocyclic ring;

each R_1 is independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_3-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, C_6-C_{12} aryl, heteroaryl, halo, OR_2 and $N(R)_2$;

each R_2 is independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_3-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, C_6-C_{12} aryl, heteroaryl and -C(O)R_5;

each R_5 is independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_3-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, C_6-C_{12} aryl, heteroaryl, C_1-C_{10} alkoxy, C_3-C_{10} alkenyloxy, C_3-C_{10} alkynyloxy, C_3-C_{10} cycloalkyloxy, C_5-C_{10} cycloalkenyloxy, C_3-C_{10} heterocycloalkyloxy, C_5-C_{10} heterocycloalkenyloxy, C_6-C_{12} aryloxy, heteroaryloxy, C_1-C_{10} alkylthio, C_3-C_{10} alkenylthio, C_3-C_{10} alkynylthio, C_3-C_{10} cycloalkylthio, C_5-C_{10} cycloalkenylthio, C_3-C_{10} heterocycloalkylthio, C_5-C_{10} heterocycloalkenylthio, C_6-C_{12} arylthio, heteroarylthio, OH, SH and $N(R)_2$;

wherein for each instance that B and/or B' is arylene, the substituents directly attached to the respective arylene rings (including arsenoxide or arsenoxide equivalent) may be in a para-, meta- or ortho- relationship; and

wherein each alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, heterocycloalkylene, heterocycloalkenylene, arylene, heteroarylene and acyl may be independently substituted with hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_3-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, C_6-C_{12} aryl, heteroaryl, cyano, cyanate, isocyanate, OR_{2a}, SR_6, nitro, arsenoxide, -S(O)R_3, -OS(O)R_3, -$S(O)_2R_3$, -OS(O)$_2R_3$, -P(O)R_4R_4, -OP(O)R_4R_4, -N(R")$_2$, -NRC(O)$(CH_2)_mQ$, -C(O)R_5;



wherein R, R_1 and R_5 are as defined above; and

R_{2a} is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, -S(O)R_3, -$S(O)_2R_3$, -P(O)$(R_4)_2$, $N(R)_2$ and -C(O)R_5;

each R_3 is independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_3-C_{10}

heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, C_6-C_{12} aryl, heteroaryl, C_1-C_{10} alkoxy, C_3-C_{10} alkenyloxy, C_3-C_{10} alkynyloxy, C_3-C_{10} cycloalkyloxy, C_5-C_{10} cycloalkenyloxy, C_3-C_{10} heterocycloalkyloxy, C_5-C_{10} heterocycloalkenyloxy, C_6-C_{12} aryloxy, heteroaryloxy, C_1-C_{10} alkylthio, C_3-C_{10} alkenylthio, C_3-C_{10} alkynylthio, C_3-C_{10} cycloalkylthio, C_5-C_{10} cycloalkenylthio, C_3-C_{10} heterocycloalkylthio, C_5-C_{10} heterocycloalkenylthio, C_6-C_{12} arylthio, heteroarylthio and $N(R)_2$;

each R_4 is independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_3-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, C_6-C_{12} aryl, heteroaryl, C_1-C_{10} alkoxy, C_3-C_{10} alkenyloxy, C_3-C_{10} alkynyloxy, C_3-C_{10} cycloalkyloxy, C_5-C_{10} cycloalkenyloxy, C_3-C_{10} heterocycloalkyloxy, C_5-C_{10} heterocycloalkenyloxy, C_6-C_{12} aryloxy, heteroaryloxy, C_1-C_{10} alkylthio, C_3-C_{10} alkenylthio, C_3-C_{10} alkynylthio, C_3-C_{10} cycloalkylthio, C_5-C_{10} cycloalkenylthio, C_3-C_{10} heterocycloalkylthio, C_5-C_{10} heterocycloalkenylthio, C_6-C_{12} arylthio, heteroarylthio, halo and $N(R)_2$;

R_6 is selected from the group consisting of C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_3-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, C_6-C_{12} aryl, heteroaryl, C_1-C_{10} alkylthio, C_3-C_{10} alkenylthio, C_3-C_{10} alkynylthio, C_3-C_{10} cycloalkylthio, C_5-C_{10} cycloalkenylthio, C_3-C_{10} heterocycloalkylthio, C_5-C_{10} heterocycloalkenylthio, C_6-C_{12} arylthio, heteroarylthio, $-S(O)R_3$, $-S(O)_2R_3$ and $-C(O)R_5$,

R" is the same as R or two R" taken together with the N atom to which they are attached may form a saturated, unsaturated or aromatic heterocyclic ring system;

Q is selected from halogen and $-OS(O)_2Q_1$; wherein Q_1 is selected from C_1-C_4 alkyl, C_1-C_4 perfluoroalkyl, phenyl, *p*-methylphenyl; and

m is 1 to 5,

n is an integer from 0 to 20

Y comprises at least one arsenoxide or arsenoxide equivalent;

p is an integer from 1 to 10, and wherein the compound of formula (I) has more than 6 carbon atoms.

12. (Currently amended) The ~~process~~ method of claim 11, wherein A is selected from the

group consisting of natural, unnatural and synthetic amino acids, hydrophilic amines, peptides, polypeptides, sugar residues, oligosaccharides, and thiol containing proteins, small acid residues, hydroxyl containing residues, or a combination thereof.

13. (Currently amended) The ~~process~~ method of claim 12, wherein said hydrophilic amine is selected from primary alkylamines, primary arylamines, primary aralkylamines, secondary alkylamines, secondary arylamines, secondary aralkylamines, tertiary alkylamines, tertiary arylamines and tertiary aralkylamines, and heterocyclic amines.

14. (Currently amended) The ~~process~~ method of claim 12, wherein A is selected from the group consisting of dipeptides, tripeptides, tetrapeptides, pentapeptides, glutathione, glucosamine, saccharides, disaccharides, oligosaccharides, wherein the sulfur atom of each sulfur containing residue may be optionally oxidised to form a sulfoxide or sulfone.

15. (Currently amended) The ~~process~~ method of claim 14, wherein A is selected from a peptide comprising one or more of cysteinylglycine, cysteic acid, aspartic acid, glutamic acid, lysine, and arginine; glucose, fructose, mannose, xylose, lyxose, galactose, hexose, sucrose, sorbose, galactosyl-sucrose, sorbitol, mannitol, and xylitol.

16. (Currently amended) The ~~process~~ method of claim 11, wherein

X is selected from the group consisting of -C(O)-, -C(S)-, -C(O)O-, C(S)O-, and -C(S)S-, or is absent;

B is selected from the group consisting of C_1-C_5 alkylene, C_2-C_5 alkenylene, C_2-C_5 alkynylene, C_3-C_{10} cycloalkylene, C_5-C_{10} cycloalkenylene, C_6-C_{12} arylene and C_2-C_5 acyl;

X' is selected from the group consisting of -O-, -S-, -NR-, -S-S-, -S(O)-, -$S(O)_2$-, -P(O)(R_1)-, -OP(O)(R_1)-, OP(O)(R_1)O-, -OP(O)(R_1)OP(O)(R_1)O-, -C(O)-, -C(S)-, -C(O)O-, C(S)O-, -C(S)S-, -Se-,



, or is absent; wherein E is O, S or $N(R)_2^+$;

n is 0, 1 or 2; and

B' is C_1-C_5 selected from the group consisting of alkylene, C_2-C_5 alkenylene, C_2-C_5 alkynylene, C_3-C_{10} cycloalkylene, C_5-C_{10} cycloalkenylene, and C_6-C_{12} arylene, or is absent; and wherein

each R is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, OR_2 and C_2-C_{10} acyl;

R' is the same as R;

each R_1 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, halo, OR_2 and $N(R)_2$;

each R_2 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, and -$C(O)R_5$;

each R_5 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_3-C_5 alkenyloxy, C_3-C_5 alkynyloxy, C_3-C_{10} cycloalkyloxy, C_5-C_{10} cycloalkenyloxy, C_6-C_{12} aryloxy, C_1-C_5 alkylthio, C_3-C_5 alkenylthio, C_3-C_5 alkynylthio, C_3-C_{10} cycloalkylthio, C_5-C_{10} cycloalkenylthio, C_6-C_{12} arylthio, OH, SH, and $N(R)_2$;

wherein for each instance that B and/or B' is arylene, the substituents directly attached to the respective arylene rings (including arsenoxide or arsenoxide equivalent), may be in a para-, meta- or ortho- relationship, and

wherein each alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, arylene, and acyl may be independently substituted with hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, cyano, halo, cyanate, isocyanate, OR_{2a}, SR_6, nitro, arsenoxide, -$S(O)R_3$, -$OS(0)R_3$, -$S(O)_2R_3$, -$OS(O)_2R_3$, -$P(O)R_4R_4$, -$OP(O)R_4R_4$, -$N(R")_2$, $NRC(O)(CH_2)_mQ$, -$C(O)R_5$,



wherein R, R_1 and R_5 are as defined above; and

R_{2a} is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, -S(O)R_3, -S(O)$_2R_3$, -P(O)$(R_4)_2$, N$(R)_2$ and -C(O)R_5;

each R_3 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_3-C_5 alkenyloxy, C_3-C_5 alkynyloxy, C_3-C_{10} cycloalkyloxy, C_5-C_{10} cycloalkenyloxy, C_6-C_{12} aryloxy, C_1-C_5 alkylthio, C_3-C_5 alkenylthio, C_3-C_5 alkynylthio, C_3-C_{10} cycloalkylthio, C_5-C_{10} cycloalkenylthio, C_6-C_{12} arylthio and N$(R)_2$;

each R_4 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_3-C_5 alkenyloxy, C_3-C_5 alkynyloxy, C_3-C_{10} cycloalkyloxy, C_5-C_{10} cycloalkenyloxy, C_6-C_{12} aryloxy, C_1-C_5 alkylthio, C_3-C_5 alkenylthio, C_3-C_5 alkynylthio, C_3-C_5 cycloalkylthio, C_5-C_5 cycloalkenylthio, C_6-C_{12} arylthio, halo and N$(R)_2$;

R_6 is independently selected from the group consisting of C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, C_1-C_5 alkylthio, C_3-C_5 alkenylthio, C_3-C_5 alkynylthio, C_3-C_{10} cycloalkylthio, C_5-C_{10} cycloalkenylthio, C_6-C_{12} arylthio, -S(O)R_3, -S(O)$_2R_3$ and -C(O)R_5,

R" is the same as R;

Q is selected from the group consisting of halogen and -OS(O)$_2Q_1$; wherein Q_1 is selected from C_1-C_4 alkyl, C_1-C_4 perfluoroalkyl, phenyl, *p*-methylphenyl;

m is 1 to 5.

17. (Currently amended) The ~~process~~ method of claim 11, wherein

X is absent;

B is selected from the group consisting of C_1-C_5 alkylene, C_6-C_{12} arylene and C_2-C_5 acyl;

X' is selected from the group consisting of -O-, -S-, -NR-, -S-S-, -S(O)-, -S(O)$_2$-, -P(O)(R_1)-, -C(O)-, -C(S)-, -C(O)O-, C(S)O-, -Se-, and



, or absent; wherein E is O, S or N$(R)_2^+$;

n is 0, 1 or 2; and

B' is C_1-C_5 alkylene, C_6-C_{12} arylene or is absent; and wherein

each R is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_3-C_{10} cycloalkyl, C_6-C_{12} aryl, OR_2 and C_2-C_5 acyl;

R' is the same as R;

each R_1 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_3-C_{10} cycloalkyl, C_6-C_{12} aryl, halo, OR_2 and $N(R)_2$;

each R_2 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_3-C_{10} cycloalkyl, C_6-C_{12} aryl and $-C(O)R_5$;

each R_5 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_3-C_5 alkenyloxy, C_3-C_{10} cycloalkyloxy, C_5-C_{10} cycloalkenyloxy, C_6-C_{12} aryloxy, C_1-C_5 alkylthio, C_3-C_5 alkenylthio, C_3-C_{10} cycloalkylthio, C_5-C_{10} cycloalkenylthio, C_6-C_{12} arylthio, OH, SH and $N(R)_2$;

wherein for each instance that B and/or B' is arylene, the substituents directly attached to the respective arylene rings (including arsenoxide or arsenoxide equivalent) may be in a para-, meta- or ortho- relationship, and

wherein each alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, arylene, and acyl may be independently substituted with hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, halo, cyano, cyanate, isocyanate, OR_{2a}, SR_6, nitro, arsenoxide, $-S(O)R_3$, $-OS(O)R_3$, $-S(O)_2R_3$, $-OS(O)_2R_3$, $-P(O)R_4R_4$, $-OP(O)R_4R_4$, $-N(R")_2$, $-NRC(O)(CH_2)_mQ$, $-C(O)R_5$,



wherein R, R_1 and R_5 are as defined above; and

R_{2a} is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_3-C_{10} cycloalkyl, C_6-C_{12} aryl, $-S(O)R_3$, $-S(O)_2R_3$, $-P(O)(R_4)_2$ and $-C(O)R_5$;

each R_3 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_3-C_{10} cycloalkyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_3-C_{10} cycloalkyloxy, C_6-C_{12}

aryloxy, C_1-C_5 alkylthio, C_3-C_{10} cycloalkylthio, C_6-C_{12} arylthio and $N(R)_2$;

each R_4 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_3-C_{10} cycloalkyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_3-C_{10} cycloalkyloxy, C_6-C_{12} aryloxy, halo and $N(R)_2$;

R_6 is selected from the group consisting of C_1-C_5 alkyl, C_3-C_{10} cycloalkyl, C_6-C_{12} aryl, C_1-C_5 alkylthio, C_3-C_{10} cycloalkylthio, C_6-C_{12} arylthio, $-S(O)R_3$, $-S(O)_2R_3$ and $-C(O)R_5$,

R" is the same as R;

Q is selected from halogen and $-OS(O)_2Q_1$; wherein Q_1 is selected from C_1-C_4 alkyl, C_1-C_4 perfluoroalkyl, phenyl, *p*-methylphenyl; and

m is 1 to 5.

18. (Currently amended) The ~~process~~ method of claim 11, wherein

X is absent;

B is selected from the group consisting of C_1-C_5 alkylene, C_6-C_{12} arylene and C_2-C_5 acyl;

X′ is selected from the group consisting of -O-, -S-, -NR-, -C(O)-, and -C(O)O-, or is absent;

n is 1; and

B' is C_1-C_5 alkylene, C_6-C_{12} arylene or is absent; and

R is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_6-C_{12} aryl and C_2-C_5 acyl;

wherein for each instance that B and/or B' is arylene, the substituents directly attached to the respective arylene rings (including arsenoxide or arsenoxide equivalent), may be in a para-, meta- or ortho- relationship, and

wherein each alkylene, arylene, and acyl may be independently substituted with hydrogen, C_1-C_5 alkyl, C_2-C_5 alkenyl, C_2-C_5 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, C_6-C_{12} aryl, halo, cyano, cyanate, isocyanate, OR_{2a}, SR_6, nitro, arsenoxide, $-S(O)R_3$, $-S(O)_2R_3$, $-P(O)R_4R_4$, $-N(R")_2$, $-NRC(O)(CH_2)_mQ$, $-C(O)R_5$,



wherein each R is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_6-C_{12} aryl and C_2-C_5 acyl;

R_{2a} is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_6-C_{12} aryl, -$S(O)R_3$, -$S(O)_2R_3$, -$P(O)(R_4)_2$ and -$C(O)R_5$;

each R_3 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_6-C_{12} aryloxy, C_1-C_5 alkylthio, and C_6-C_{12} arylthio;

each R_4 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_6-C_{12} aryloxy, C_1-C_5 alkylthio, C_6-C_{12} arylthio, halo and $N(R)_2$;

each R_5 is independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, C_6-C_{12} aryloxy, C_1-C_5 alkylthio, C_6-C_{12} arylthio, OH, SH and $N(R)_2$;

R_6 is selected from the group consisting of C_1-C_5 alkyl, C_6-C_{12} aryl, C_1-C_5 alkylthio, C_6-C_{12} arylthio, -$S(O)R_3$, -$S(O)_2R_3$ and -$C(O)R_5$,

R" is the same as R above;

Q is selected from halogen and -$OS(O)_2Q_1$; wherein Q_1 is selected from C_1-C_4 alkyl, C_1-C_4 perfluoroalkyl, phenyl, *p*-methylphenyl; and

m is, 2, 3, 4, or 5.

19. (Currently amended) The ~~process~~ method of claim 11, wherein

X is absent;

B is C_2-C_5 acyl;

X' is NR;

n is 1;

B' is phenylene; and

R is H;

wherein the substituents directly attached to the phenylene ring may be in a para-, meta- or ortho- relationship.

20. (Currently amended) The ~~process~~ method of claim 19, wherein said compound is:



wherein R_7 to R_{10} are independently selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_6-C_{12} aryl, halogen, hydroxy, amino, nitro, carboxy, C_1-C_5 alkoxy, $-OS(O)_2R_3$ and $-NHC(O)CH_2Q$ wherein Q is halogen, $-OS(O)_2CH_3$, $-OS(O)_2C_6H_5$ and $-OS(O)_2$-*p* tolyl; and wherein, when any one of R_7 to R_{10} is C_1-C_5 alkyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, $-OS(O)_2R_3$ it is capable of forming a fused ring with the phenylene; and further wherein, at least one of R_7 to R_{10} is C_1-C_5 alkyl, C_6-C_{12} aryl, C_1-C_5 alkoxy, or $-OS(O)_2R_3$, in combination with at least any one other of R_7 to R_{10}, is capable of forming a fused ring with the phenylene.

21. (Currently amended) The ~~process~~ method of claim 20, wherein R_7 to R_{10} are independently selected from the
group consisting of hydrogen, halogen, hydroxy, amino, nitro, cyano, carboxy, C_1-C_5 alkoxy, methyl, ethyl, isopropyl, tert-butyl, phenyl and $-NHC(O)CH_2Q$ wherein Q is halogen, $-OS(O)_2CH_3$, $-OS(O)_2C_6H_5$ and $-OS(O)_2$-*p* tolyl .

22. (Currently amended) The ~~process~~ method of claim 19, wherein the arsenoxide (-As=O) group is at the 4-position of the phenylene ring.

23. (Currently amended) The ~~process~~ method of claim 1, wherein the compound is selected from the group consisting of:





































and



24. (withdrawn) The process of claim 1, wherein the compound is represented by Formula VII:



(VII)

wherein G is selected from the group consisting of: hydrogen, halogen, hydroxy, amino, nitro, carboxy, C_1-C_5 alkoxy, C_1-C_5 alkyl and C_6-C_{12} aryl and -NHC(O)CH_2Q wherein Q is halogen, -OS(O)$_2CH_3$, -OS(O)$_2C_6H_5$ or -OS(O)$_2$-p tolyl; and
the arsenoxide group (-As=O) is optionally replaced by an arsenoxide equivalent as defined herein.

25. (withdrawn) The process of claim 24, wherein G is selected from the group consisting of: hydrogen, halogen, hydroxy, amino, nitro, carboxy, C_1-C_5 alkoxy, methyl, ethyl, iso-propyl, tertbutyl, phenyl, and -NHC(O)CH_2Q wherein Q is halogen, -OS(O)$_2CH_3$, -OS(O)$_2C_6H_5$ or -OS(O)$_2$-p tolyl.

26. (withdrawn) The process of claim 24, wherein G is selected from the group consisting of hydroxy, fluorine, amino, and nitro.

27. (withdrawn) The process of claim 24, wherein the arsenoxide group (-As=O) is replaced by an arsenoxide equivalent as defined herein.

28. (withdrawn) The process of claim 27, wherein the arsenoxide equivalent is any dithiol reactive species that shows essentially the same affinity towards dithiols as -As=O.